The functional tumour immunology team are studying how the immune system is affected by breast cancer so that they can develop new targeted treatments for the disease.

Professor Kristijan Ramadan is investigating how triple negative breast cancer can become resistant to drugs called PARP inhibitors and what treatments we could use next.

Professor Nick Lakin and his PhD student want to find signs that breast cancer cells are becoming resistant to drugs called PARP inhibitors and find new weaknesses in tumours that don’t respond to these drugs.

Professor Elinor Sawyer is looking for new ways to tell which lobular breast cancer patients may benefit from personalised therapies. She believes the environment within and around the tumour may hold a clue.

Professor Ross Chapman’s project will help us better understand how changes in the BRCA1 gene make breast cancer more likely. It’ll also help unpick why some breast cancer cells develop resistance to PARP inhibitor drugs.

Professor Tyson Valentine Sharp is working to understand how a protein called CoAsy is linked to breast cancer. He hopes this could lead to a new targeted treatment for triple negative breast cancer